NuVasive shares dropped 13 percent after the company announced receiving a subpoena related to potentially false or improper Medicare and Medicaid claims, erasing more than $100 million in share value, according to a UT San Diego report.
The company disclosed receiving a subpoena from the Office of the Inspector General of the U.S. Department of Health Services on Tuesday seeking documents from January 2007 to April 2013.
The company also announced second quarter revenue increase of 7.3 percent recently, reaching $165.7 million. However, the company reported GAAP net loss of $6.5 million during the second quarter. The company reported a $7.9 million charge related to royalty accruals in connection with the company's patent litigation with Medtronic.
More Articles on Orthopedic and Spine Devices:
Lanx Publishes Favorable Study for ASPEN Minimally Invasive Spinal Fusion Device
Integra LifeSciences Receives FDA Clearance for Titan Reverse Shoulder System
DJO Global Posts $20.6M Net Loss in Q2